ライフサイエンスコーパス: autologous T cell

1 anoma cells and used to stimulate peripheral autologous T cells.

2 sed to present a recombinant Sp17 protein to autologous T cells.

3 g of blood-derived dendritic cells (DCs) and autologous T cells.

4 nctional in stimulating the proliferation of autologous T cells.

5 ts in immunodeficient mice co-engrafted with autologous T cells.

6 (-)CTLA-4(+) and suppressed proliferation of autologous T cells.

7 eric antigen receptor (CAR) engineering into autologous T cells.

8 aneous recognition of neoantigens (NeoAg) by autologous T cells.

9 tetanus toxoid complexes and cocultured with autologous T cells.

10 ected with NTHi in vitro and cocultured with autologous T cells.

11 eration and IFN-gamma and IL-17 responses of autologous T cells.

12 ly reduced functional responses to activated autologous T cells.

13 e pulsing them with HIV and mixing them with autologous T cells.

14 subsequent MDDC maturation and activation of autologous T cells.

15 with JAK3 mutations despite the presence of autologous T cells.

16 e, with residual development and function of autologous T cells.

17 c dendritic cells (moDC) and co-culture with autologous T cells.

18 tin synapse formation in both allogeneic and autologous T cells.

19 gamma production by M. tuberculosis-specific autologous T cells.

20 e, using genetically redirected syngeneic or autologous T cells.

21 n CD34(+) hematopoietic progenitor cells and autologous T cells.

22 tion and suppressed IL-17 in cocultures with autologous T cells.

23 on and IL-5, but not IFNgamma, production by autologous T cells.

24 c cells compared with cotransplantation with autologous T cells.

25 imulate proliferation of both allogeneic and autologous T cells.

26 te proliferation and IFN-gamma production by autologous T cells.

27 cation of tumor antigens (TAs) recognized by autologous T cells.

28 -stimulated DCs led to targeted expansion of autologous T cells against tumor-associated antigens, in

29 responsive cells suppressed proliferation of autologous T cells, an effect that was dependent on IL-1

30 d and tested different subsets and ratios of autologous T cells and APCs as well as the resting perio

31 t the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineer

32 The DCs were coincubated with autologous T cells and the cytolytic activity of the T c

33 ts were cocultured with resting or activated autologous T cells and their activation was assessed by

34 rbital decompression surgery were mixed with autologous T cells, and fibroblast proliferation was det

35 The EBV-LCL J1s were cocultured with autologous T cells, and the proliferative and cytotoxic

36 Significantly, the results show that autologous T cells are primed by the fusion cells to ind

37 Autologous T cells armed with the human NKG2D CAR effect

38 ing of gene therapies, use of gene corrected autologous T cells as an alternative strategy for some P

39 d by ex vivo anti-CD3/anti-CD28 costimulated autologous T cells at day 2 after transplantation.

40 ns expressed CD25 and reacted with activated autologous T cells but not resting T cells, irrespective

41 and/or heavily pretreated with chemotherapy, autologous T cells can be difficult to harvest in suffic

42 To determine whether autologous T cells can drive proliferation of orbital fi

43 Four infusions of autologous T cell clones were administered, the first wi

44 utation in FOXP3, allowing the comparison of autologous T-cell clones that do or do not express FOXP3

45 ing MDRCs, which stimulated proliferation of autologous T cells, comprised a high fraction of MDRCs i

46 ulatory cells, since their addition to fresh autologous T cells cultured with autologous nontransduce

47 CD3-bispecific antibody (bsAb) that recruits autologous T-cell cytotoxicity against CLL cells in vitr

48 t intense immunosuppressive conditioning and autologous T-cell-depleted hematopoietic transplantation

49 ells, because similarly activated polyclonal autologous T cells did not have this effect.

50 Patients with less profoundly impaired autologous T-cell differentiation are designated as havi

51 Autologous T cells directed to the LMP2 or LMP1 and LMP2

52 Adoptive immunotherapy using autologous T cells endowed with chimeric antigen recepto

53 Autologous T cells engineered to express a CD19-specific

54 The adoptive transfer of autologous T cells engineered to express a chimeric anti

55 trial to evaluate the safety and activity of autologous T cells engineered to express an affinity-enh

56 ular chimera), engineered to express several autologous T cell epitopes and sequences derived from th

57 on of CD14(+)HLA-DR(lo/-) MDSC that suppress autologous T cells ex vivo in a STAT-3-dependent manner.

58 ss proliferation and IFN-gamma production by autologous T cells ex vivo.

59 g DC-stimulated autologous T cells than with autologous T cells expanded by culture with interleukin-

60 Autologous T cells expressing a CD19-specific chimeric a

61 The production of autologous T cells expressing a chimaeric antigen recept

62 r, some patients fail to respond due to poor autologous T cell fitness.

63 vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster i

64 ted EBNA-3A peptide, FLRGRAYGL, and added to autologous T cells for 7 days at a DC:T ratio of 1:5 to

65 yte-restricted antigen that is recognized by autologous T cells from a patient with melanoma.

66 d patient tumor and lymphocytes showing that autologous T cells from cancer patients can be engineere

67 ellular antigens by dendritic cells (DCs) to autologous T cells from healthy donors.

68 D40 ligand, leading to strong stimulation of autologous T cells from HIV-1-infected individuals, but

69 e tumor cell lines, primary macrophages, and autologous T cells from patients with prostate cancer.

70 Autologous T cells from patients with SLE were transduce

71 that these cells can drive a Th1 response in autologous T cells from sensitized individuals.

72 ffect on the activation and proliferation of autologous T cells from the peritoneal cavity of patient

73 using a Theileria-transformed cell line and autologous T cells from Theileria-infected cattle.

74 Autologous T cell gene therapy may offer a cure without

75 preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a c

76 ma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporati

77 with relapsed B-cell lymphomas treated with autologous T cells genetically modified to express a CD2

78 emia (NHL/CLL) or multiple myeloma (MM) with autologous T cells genetically modified to express kappa

79 s expressed by tumor cells and recognized by autologous T cells has led to the prospect of treating c

80 Therapy with genetically modified autologous T cells has shown great promise in cancer the

81 ell as melanoma cells for which responses by autologous T cells have been detected.

82 cted patients are infected and cultured with autologous T cells, IL-10 was produced in 6 of 10 patien

83 cells (PSCs) has the potential to transform autologous T cell immunotherapy by facilitating universa

84 Immunogenic neo-epitopes were recognized by autologous T cells in 3 of 4 patients who utilized the d

85 ith advanced stage melanoma, which inhibited autologous T cells in a manner relying up prostaglandin

86 In contrast, CWRBA-transduced DCs primed autologous T cells in an antigen-specific, MHC-restricte

87 rthritis elicit spontaneous proliferation of autologous T cells in an HLA-DR and CD47 costimulation-d

88 as reduced compared with cultures containing autologous T cells in the presence of Ag.

89 gG, and IgE Abs when they were cultured with autologous T cells in the presence of IL-4.

90 atient-derived human melanoma cells by their autologous T cells in vitro and potentiates responses to

91 helper T cell 1 (Th1) cytokine expression by autologous T cells in vitro more potently than memory B

92 ors were used as APC to present HIV-1 Ags to autologous T cells in vitro, the strength and specificit

93 nduce a suppressive, regulatory phenotype in autologous T cells in vitro; these patients tended to ha

94 Coculture of adult RSV-infected DCs with autologous T cells induced secretion of gamma interferon

95 sely, coculture of cord RSV-infected DCs and autologous T cells induced secretion of IL-4, IL-6, IL-1

96 IL-10-producing monocytes cocultured with autologous T cells inhibited the proliferation of the T

97 However, an increase in autologous T-cell killing of patient MM cells could not

98 ypical SCID must have less than 0.05 x 10(9) autologous T cells/L on repetitive testing, with either

99 Coculture of DCs with autologous T cells leads to an increase in both the numb

100 ture of mature DCs from X-HIGM patients with autologous T cells led to low IFN-gamma production, wher

101 We conducted a phase I study of autologous T cells lentivirally-transduced with a fully-

102 Of note, very low numbers of autologous T cells (<0.05 x 10(9)/L) characterized typic

103 ia (ALL) we have enrolled for treatment with autologous T cells modified to express 19-28z, a second-

104 rm and developed cancer vaccines composed of autologous T cells modified with tumor antigens and addi

105 The role of autologous T cells needs further delineation but may hel

106 that two distinct proliferative responses of autologous T cells occur in vivo in a lymphopenic settin

107 variable fragment clone, but was higher with autologous T-cell origin (727 [83%, 78.5-86.5, I(2)=44.3

108 were able to repress proliferation of their autologous T cells preactivated by CD2, CD3, and CD28.

109 BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood,

110 splantation vaccine and infusion of a primed autologous T-cell product in stimulating specific immuni

111 omly assigned to receive an influenza-primed autologous T-cell product or a nonspecifically primed au

112 The provision of a primed autologous T-cell product significantly improved subsequ

113 To that end, we clinically tested an autologous T-cell product that targets multiple tumor-as

114 Patients who received the influenza-primed autologous T-cell product were significantly more likely

115 s T-cell product or a nonspecifically primed autologous T-cell product.

116 lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same

117 Most trials utilized autologous T cell products to avoid immune rejection yet

118 oduced proinflammatory cytokines, stimulated autologous T cell proliferation and IFN-gamma secretion,

119 1, enabling LOX-1(+) neutrophils to suppress autologous T cell proliferation in vitro.

120 itic cells to apoptotic non-T cells augments autologous T cell proliferation, and blockade of alpha(v

121 tor population is essential for induction of autologous T cell proliferation, suggesting that cellula

122 CD25(+) T cells mediate potent inhibition of autologous T cell proliferation.

123 ls is associated with augmented induction of autologous T cell proliferation.

124 non-T cells or dendritic cells to stimulate autologous T cell proliferation.

125 the functional potency of DCs and stimulated autologous T cell proliferation.

126 fect on IL-10 production, for both allo- and autologous T cell proliferation.

127 set that was the most efficient in promoting autologous T cell proliferation.

128 gp120-treated mDCs downregulated autologous T-cell proliferation and IFN-gamma production

129 These MDSC-like cells potently suppress autologous T-cell proliferation and IFN-gamma production

130 d P brasiliensis-pulsed mature DCs to induce autologous T-cell proliferation, generation of T helper

131 gulate costimulatory molecules and stimulate autologous T-cell proliferation.

132 All 3 showed early autologous T-cell reconstitution following allogeneic he

133 nic epitopes in human idiotype recognized by autologous T cells remain largely unknown.

134 se studies demonstrate that EC can stimulate autologous T cell responses to CMV in the absence of acc

135 darTreg selectively suppressed autologous T cell responses to donor antigens in vitro.

136 niquely allows for the in vivo evaluation of autologous T cell responses while avoiding graft-versus-

137 MDSCs were suppressive of autologous T-cell responses as evidenced by reduced T-ce

138 atocytes, or with HCV core protein, suppress autologous T-cell responses.

139 Most patients with autologous T cells still have profound TD, as defined by

140 Autologous T cells stimulated proliferation of orbital f

141 Autologous T cells stimulated with in vitro-generated, l

142 Immunization with irradiated autologous T cells (T cell vaccination) is shown to indu

143 ) T-cell therapy, using genetically modified autologous T cells targeting CD19, has been approved for

144 urfold to sixfold higher using DC-stimulated autologous T cells than with autologous T cells expanded

145 ction of RIbeta cDNAs from SLE subjects into autologous T cells that do not synthesize the RIbeta sub

146 We used autologous T cells that express a CD19-directed CAR (CTL

147 treated with a single infusion of 16.2x10(9) autologous T cells that had been genetically engineered

148 atients had infusions on day 14 after HCT of autologous T cells that had been stimulated using beads

149 Autologous T cells that have been genetically modified t

150 psed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retrov

151 cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated

152 and Transwell studies showed suppression of autologous T cells to be contact dependent.

153 rly attenuated the proliferative response of autologous T cells to SEB.

154 with Hd-AdV stimulated the proliferation of autologous T cells to the same level as DCs transduced w

155 Autologous T cells transduced to express a high affinity

156 We infused autologous T cells transduced with a CD19-directed chime

157 aluate the ability of adoptively transferred autologous T cells transduced with a T-cell receptor (TC

158 L019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric

159 ide a rationale for target selection towards autologous T cell, vaccine, and antibody-based therapeut

160 condary resistance, heterogeneous quality of autologous T cells, variable persistence, and low activi

161 Proliferation of allogeneic and autologous T cells was observed when MVA-TRICOM-infected

162 wed that transmission of HIV-1 from MDDCs to autologous T cells was significantly reduced in the pres

163 Autologous T cells were engineered via an 11-day manufac

164 Graded doses of autologous T cells were infused after CHOP chemotherapy

165 te treatment induces nAPCs that can activate autologous T cells when using neutrophils from individua

166 d briskly in response to allogeneic, but not autologous, T cells when mixed with irradiated T cells f

167 malignancies, but current approaches rely on autologous T cells, which are difficult and expensive to

168 33(+) MDSCs inhibited IFN-gamma release from autologous T cells, which was restored upon ROS and iNOS

169 esized that combining adoptively transferred autologous T cells with a cancer vaccine strategy would

170 1.23x106/kg [manufactured by transduction of autologous T cells with a CD19 lentiviral vector and amp

171 ocytes, generated in vitro by stimulation of autologous T cells with MVA-TRICOM-infected CLL cells, s

172 ng cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the fea